Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose licensed influenza vaccine in adults aged 50 and older. The study, known as ...

The U.S. Centers for Disease Control and Prevention has merged H5N1 bird flu updates with routine updates for seasonal ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...

Moderna said that the result – which showed its shot was around 26.6% more effective than the comparator – sets up regulatory filings both for mRNA-1010 and its combination flu and COVID-19 ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu vaccine candidate compared to a standard-dose licensed flu vaccine in adults ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Moderna reports positive results from phase 3 efficacy study of P304 for seasonal influenza vaccine: Cambridge, Massachusetts Wednesday, July 2, 2025, 16:00 Hrs [IST] Moderna, Inc ...